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Abstract
It has been reported that increasingly microRNAs are associated with diseases. However, the patterns among the microRNA-
disease associations remain largely unclear. In this study, in order to dissect the patterns of microRNA-disease associations, we
performed a comprehensive analysis to the human microRNA-disease association data, which is manually collected from
publications.WebuiltahumanmicroRNAassociateddiseasenetwork.Interestingly,microRNAstendtoshowsimilarordifferent
dysfunctional evidences for the similar or different disease clusters, respectively. A negative correlation between the tissue-
specificity of a microRNA and the number of diseases it associated was uncovered. Furthermore, we observed an association
between microRNA conservation and disease. Finally, we uncovered that microRNAs associated with the same disease tend to
emerge as predefined microRNA groups. These findings can not only provide help in understanding the associations between
microRNAs and human diseases but also suggest a new way to identify novel disease-associated microRNAs.
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Introduction
MicroRNAs (miRNAs) are a class of small non-coding RNAs
(,22 nt) which normally function as negative regulators of target
mRNA expression at the posttranscriptional level. They bind to
the 39UTR of target mRNAs through base pairing, resulting in
target mRNAs cleavage or translation inhibition[1,2,3]. It has also
recently been demonstrated that miRNAs may function as positive
regulators in some cases[4,5]. It is estimated that 1–4% genes in
the human genome are miRNAs and a single miRNA can regulate
as many as 200 mRNAs[6]. There is increasing evidence
suggesting that miRNAs play critical roles in many key biological
processes, such as cell growth, tissue differentiation, cell prolifer-
ation, embryonic development, and apoptosis[6]. We previously
found that miRNA also play important roles in cellular signaling
network[7], cross-species gene expression variation[8], and co-
regulation with transcription factors[9]. As such, mutation of
miRNAs, dysfunction of miRNA biogenesis and dysregulation of
miRNAs and their targets may result in various diseases.
Currently, there have been reported ,70 diseases are associated
with miRNAs (see our database http://cmbi.bjmu.edu.cn/hmdd.).
Many studies have produced a large number of miRNA-disease
associations and shown that the mechanisms of miRNAs involved
in diseases are very complex. In such a complex case, a
comprehensive analysis of these data will do great help in
understanding the associations between miRNAs and diseases.
Furthermore, a large-scale analysis and integration of these
miRNA-disease associations will offer a platform to dissect the
patterns of the miRNA and disease associations, even though
current known miRNA-disease associations are far from com-
pleteness. In this study, we reported our literature-based
generation of miRNA-disease associations and the analysis of
these data based on bioinformatics.
Results
The human miRNA disease database
We retrieved miRNA-disease associations from ,100 papers
and built a human miRNA-associated disease database (HMDD),
which contains miRNA names, disease names, dysfunction
evidences, and PubMed ID. HMDD is publicly accessible at
website: http://cmbi.bjmu.edu.cn/hmdd. This database was built
on November 2007 and the data at that time was used in the
following analysis. The last update was made on July 2008. The
miRNA-disease association data between November 2007 and
July 2008 was used to validate the main results in this study.
Dysfunctional evidences in the clusters of the miRNA-
associated disease network
A bipartite graph can be used as a network model to connect two
disjoint sets of nodes [10,11]. As shown in Supplementary Figure S1,
a bipartite graph contains two sets of nodes. And nodes in the same
set are not connected and edges only exist between nodes from
different sets. Here, we constructed a bipartite graph consisting of two
disjoint sets of nodes based on the associations between a list of
miRNAsandalistofhumandiseasesobtainedfromHMDD.Oneset
contains human miRNA-associated diseases (69 diseases) and the
other set contains disease-associated miRNAs (238 miRNAs). Based
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miRNA-associated disease network (MDN) by giving two diseases an
edge if they share at least one common associated miRNA. The
MDN networkshows cluster structures (Supplementary Figure S2), in
which similar diseases are clustered together. All cancers are
connected together (Supplementary Figure S2), suggesting that
various cancers may share similar associations at the miRNA level,
in which some strong onco-miRNAs or miRNA suppressors may play
key roles. For example, miR-21 is overexpressed in various cancers
from almost all studies, showing a feature of strong onco-miRNAs,
whereas miR-125a shows down-regulation in various cancers,
suggesting that it isa miRNA suppressor. Similarly, all cardiovascular
diseases are also connected together, which may result from some
cardiovascular disease related miRNAs, such as miR-1 and miR-133,
which play roles in almost all cardiovascular diseases in the MDN.
The cancer cluster is clearly separated from the cardiovascular
disease cluster (Supplementary Figure S2). These two clusters are
connected with each other through only several hub diseases, such as
heart failure, cardiac hypertrophy, and skeletal muscle hypertrophy.
One exception is neointimal hyperplasia, a cardiovascular disease,
which is predominantly connected to the cancer cluster and has only
two connections to other cardiovascular diseases. Thus, it may share
more common miRNA associations with cancers than with
cardiovascular diseases.
Diseases in the same cluster are highly interconnected; for
example, each node connects to an average of 26 other cancers in
the cancer cluster and 9 other cardiovascular diseases in the
cardiovascular disease cluster, whereas cancers connect to only 5
cardiovasculardiseaseson average.Disease-associated miRNAsshow
various dysfunctions, such as mutation, up-regulation, deleted, and
down-regulation. However, it remains unclear whether diseases
sharing the same miRNAs have the same miRNA dysfunctions.
Because most of the reported miRNA dysfunctions are either up-
regulationordown-regulation,wecuratedmostofthedysfunctionsin
the human miRNA disease database into these two groups. We
assigned terms such as ‘‘deleted’’ and ‘‘low expressed’’ into the down-
regulation group and terms such as ‘‘overexpressed’’, ‘‘highly
expressed’’, and ‘‘over expression’’ into the up-regulation group.
We next investigated the dysfunctional patterns within the same
cluster as well as between different clusters. We calculated the
number of the same dysfunctions (both up-regulation or both down-
regulation) and the number of different dysfunctions (one shows up-
regulation and the other shows down-regulation) for miRNAs that
link diseases within the cancer cluster, or the cardiovascular disease
cluster (intra-cluster), and between cancer and cardiovascular disease
clusters (inter-cluster). Most of the shared miRNAs show the same
dysfunctions in diseases in the same clusters, for example, 82% (578/
706) of the disease pairs in the cancer cluster show the same
dysfunctions and 77% (68/88) of the disease pairs in the
cardiovascular disease cluster show the same dysfunctions (Table 1).
However, only 54% (92/170) of the paired diseases between the
cancer cluster and the cardiovascular disease cluster shows the same
dysfunctions(Table1).Diseasesindifferentclustersthusshowalarger
fraction of different miRNA dysfunctions (P=5.97610
213,F i s h e r ’ s
Exact Test). For example, miR-195 is up regulated in all reported
cardiovascular diseases and down regulated in all reported cancers.
This result suggested that although different classes of diseases
associated with common miRNA, the underlying association
mechanisms might be different.
miRNA tissue specificity and miRNA related diseases
It has been reported that tissue-specific miRNAs are often
implicated in diseases related to specific tissues[12,13,14].
However, it remains largely unknown whether there is a
correlation between the tissue specificity of a miRNA and the
number of diseases associated with it. In order to dissect this
question, we first obtained the miRNA expression profiles of 345
miRNAs across 40 normal tissues from a recently published
paper[15]. We then used the tissue specificity index t to measure
the tissue specificity of a miRNA[16]. The t value ranges from 0 to
1. A higher t value indicates higher tissue specificity of that
miRNA. We next classified the human disease related miRNAs
into several groups according to the number of diseases in which a
miRNA is implicated. We then calculated the average tissue
specificity index value for each group of miRNAs. Finally, we
observed a negative correlation between the tissue specificity index
and the number of diseases in which a miRNA is implicated
(Figure 1, R=20.83, P=0.058, Spearman’s correlation). Most of
the miRNAs associated with a large number of diseases (.=4)
show low tissue specificity index values (Figure 1). However, there
are a few outliers; miR-372, miR-373, and miR-206 that are
associated with 5, 4, and 4 diseases, whereas they show high tissue
specificity index values of 0.86, 0.82, and 0.78, respectively. miR-
372 and miR-373 are specifically expressed in placenta, while
miR-206 is specifically expressed in skeletal muscle. We also noted
that some miRNAs associated with only one disease show low
tissue specificity, which may mainly result from the incompleteness
of the miRNA-disease associations, that is, currently only one
disease was reported to associate with that miRNA. As the
research going on, more diseases would be reported to associate
with these low tissue specific miRNAs. This result revealed a
potential correlation between miRNA tissue specificity and
disease, which may be of value in predicting specific disease-
related miRNAs by combining the miRNA tissue specificity
values. Thus, if a disease occurs specifically in a given tissue, the
miRNAs specifically expressed in that tissue will have a great
potential to be related to that disease. However, most of the tissue
specific miRNAs have not been reported related to diseases. Using
this method, we detected miRNAs that show high tissue specificity
(using t.=0.80 as a cutoff, Supplementary Text S1), which are
potentially associated with that tissue-specific diseases. The
dissection of these relationships will be valuable for studying the
functions of these miRNAs and their mechanisms in diseases and
can be used to discovering novel disease-associated miRNAs.
miRNA conservation and miRNA related diseases
It has been reported that there exists a significant association
between a gene’s (protein’s) connectivity and its conservation in
yeast Saccharomyces cerevisiae [17] and human [18]. It is
expected that if a gene is evolutionarily conserved it would have
more connections to other genes and be more lethal when
Table 1. The miRNA dysfunction pattern of diseases in the
same clusters and between clusters.
Diseases
pairs In cluster1 In cluster2 Intra-cluster Between-clusters
Num1 578 68 646 92
Num2 128 20 148 78
P value P=5.97610
213
Cluster 1 is the cancer cluster.
Cluster 2 is the cardiovascular disease cluster.
Num1 is the number of the same dysfunction evidences.
Num2 is the number of different dysfunction evidences.
P value was calculated using Fisher’s Exact Test.
doi:10.1371/journal.pone.0003420.t001
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with a higher probability. However, it remains largely unknown
whether this association exists for human miRNAs and diseases.
To investigate this issue, we classified all the human disease-
associated miRNAs into two groups: miRNAs that are conserved
in other species (group 1) and miRNAs that are human specific
(group 2). We assigned one human miRNA into the conserved
miRNAs if its family members can be found in other species
according to the family annotations of miRBase[19]. Otherwise,
we assigned it into the human-specific group. We counted the
number of miRNAs that are associated with at least one disease or
zero disease for these two groups. Our results show that miRNAs
in group 1 tend to be associated with diseases with a higher
probability significantly (P=3.9610
233, Fisher’s Exact Test,
Table 2).
Single nucleotide polymorphisms (SNPs) are the most common
genetic variants in the human genome[20] and SNP density can
be used as a metric of the conservation of DNA sequences. We
calculated the number of SNPs for miRNAs associated with at
least one disease and no diseases. For all 236 miRNAs associated
with disease in our dataset, we identified 20 SNPs in 20 miRNAs
precursor sequences. The SNP occurring probability is 0.0847
(20/236). The SNP occurring probability of miRNAs that are not
associated with diseases is 0.2727 (81/297). Significantly, miRNAs
associated with diseases show lower SNP occurring probability
than miRNAs that are not associated with diseases (P=1.3610
28,
Fisher’s exact test, Figure 2). Similar result was found when
searching SNPs in mature miRNA sequences (SNP occurring
probability 0.0381 vs. 0.0707, P=0.07). We also tested the
significance by randomly picking up the same number of miRNAs
as the number of miRNAs associated with diseases from the whole
miRNAs and calculated SNP occurring probability in this group of
miRNAs, which was then compared with the real SNP occurring
probability. We repeat this process 5000 times and got the P value
(P,2.0610
24, Figure 3). These findings suggested that miRNA
conservation is associated with human disease susceptibility, which
will help in the understanding of miRNAs’ roles in diseases.
miRNA sets and miRNA diseases
The dysfunction of genes in a gene set, such as a signaling
pathway or a biological process often result in the same disease.
However, it is unclear whether miRNAs implicated in the same
disease tend to emerge as miRNA sets. In this study, we defined two
types of miRNA sets: miRNA families that contain groups of
homologous miRNAs (miRNA duplicates) and miRNA clusters that
contain groups of neighboring miRNAs on the human genome.
It has been reported that duplicates of protein coding genes are
functionally interchangeable[21], suggesting that they may be
involved in similar biological processes with similar roles,
therefore, may be implicated in the same disease. However, it is
of keen interests but remain unclear whether a family of miRNAs
tend to play roles in the same disease. In this study, we revealed
that miRNAs in 57% of the diseases have at least one family
member in that disease associated miRNAs, which is significantly
higher than the random (P=2.0610
24, Randomization Test). For
example, 50% (3/6) of the miRNAs in miR-8 family was related to
the thyroid cancer. This finding suggested that the miRNA family
members might have similar functions and play roles in similar
biological processes, and therefore whose dysfunction would lead
to similar phenotype.
Bartel and his colleagues reported that neighboring miRNAs
show significant coexpression by a microarray profiling analy-
Figure 1. The association of miRNA tissue specificity and the
number (Nd) of diseases it implicated in. Each blue circle
represents a miRNA whose x,y coordinates are its Nd and its tissue
specificity index value. MiRNAs are grouped into different groups
according to the Nd, and then the average tissue specificity index value
of each group was calculated, shown as pink triangle. The pink triangles
are connected with green lines.
doi:10.1371/journal.pone.0003420.g001
Figure 2. SNP occurring probability of miRNAs implicated in at
least one disease (disease miRNA), and miRNAs that are not
reported to be implicated in disease (no-disease miRNAs).
doi:10.1371/journal.pone.0003420.g002
Table 2. The number of miRNAs implicated in one or more
than one human diseases for two groups.
Group1 Group2
Num1 191 128
Num2 213 1
P value 3.9610
233
Groups1 contains 404 human miRNAs conserved in other species.
Group2 contains 129 human specific miRNAs.
Num1 is the number of miRNAs that are not reported related to disease.
Num2 is the number of miRNAs implicated in at least one disease.
P value was calculated using Fisher’s Exact Test.
doi:10.1371/journal.pone.0003420.t002
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may be associated with the same disease. To investigate this issue,
we identified miRNA clusters that contain neighboring miRNAs
and then analyzed the relationship of miRNA clusters and
diseases. We found that miRNAs in 46% of the diseases have at
least one neighboring member, which is significantly higher than
the random (P=2.0610
24, Randomization Test). For example, all
the 6 miRNAs implicated in hematopoietic malignancies are
located in the miR-17 cluster. This result indicated that
neighboring miRNAs might be regulated by common regulators
at similar conditions and function together, and then whose
dysfunctions would result in the same disease.
According to the miRNA family and miRNA cluster analysis
above, if most members in a miRNA set are associated with one
disease, the other members will have a great probability to be
associated with that disease too. Therefore, this finding can be
used to guide us to predict novel diseases-associated miRNAs.
Validation in new dataset
All the above analysis was performed on the miRNA-disease
association data before November 2007. In order to test the
validation of the main results, here we take the miRNA-disease
association data between November 2007 and June 2008 to validate
the main patterns we found. We first investigated the dysfunctions of
miRNAs in similar diseases and different diseases. As a result, 69%
(18/26) of the disease pairs in the same class (cancer or other
diseases) show similar miRNAs dysfunctions, which is higher than
that (33%, 5/15) of the disease pairs between difference disease
classes (P=0.03, Fisher’s Exact Test). For example, 5 of the 6 papers
revealed a down-regulation of let-7 in cancers, which is consistent
with previous report. While all papers reported an up-regulation of
let-7 in Alzheimer’s disease (see our HMDD database). In the new
dataset,miR-195 wasreportedtobedownregulatedinhumanB cell
lymphomas[23], which is also consistent with the previous results.
We nexttested the tissue specificity and disease issue. In our analysis,
miR-9 has the highest expression in brain and has a high tissue
specificityindex (0.63), whichis predicted to be associated with brain
related diseases. Later research revealed that miR-9 is associated
with Alzheimer’s disease[24], which supported our prediction. MiR-
126 has the highest expression in cardiovascular tissues in our
analysis and was reported has high heart specificity[25], and
therefore was predicted to be associated with cardiovascular disease
and validated by later research[26], in which Harris et al. found
miR-126 is associated with vascular inflammation. The SNP
occurring probability of miRNAs that are associated with diseases
in the new data is 0.0532 (5/94), which is even less than the SNP
occurring probability of miRNAs that are associated with diseases in
the original data (0.0847). For the miRNA set, we found that
miRNAs in 59% (13/22, similar with the original percentage 57%)
of the diseases have at least one family member in that disease-
associated miRNAs and miRNAs in 45% (10/22, similar with the
original percentage 46%) of the diseases have at least one cluster
member inthatdisease-associated miRNAs.Theseresultsinthe new
data suggest the patterns we found are valid and robust.
Discussion
In a conclusion, we integrated the published human miRNA
diseaseassociationsand performedacomprehensiveanalysistothese
association data. We uncovered some important patterns between
miRNAsandhumandiseases.Thesefindingswillprovidehelpinnot
only the understanding of human disease and miRNAs but also the
identification of novel disease biomarkers at the miRNA level.
Although the study of miRNAs and diseases is an ongoing
process and the miRNA-disease association data are far from
completeness, our analysis have uncovered statistically significant
patterns of miRNA-disease associations. On the other hand, we
also noted that some information could not be provided by our
analysis. For example, several brain related diseases such as
schizophrenia, Parkinson’s disease, and neurodegeneration, are
not connected to each other in this study. This probably resulted
from the incompleteness of the current data. As more compre-
hensive data becomes available, it will do great help to similar
analysis in the future. Another limitation of the current data is that
some diseases are not at the same level. For example, B cell
lymphoma and mantle cell lymphoma are both belong to
lymphoma. Although limitations exist in the current data, the
patterns uncovered here is important for understanding the
association of miRNAs and various diseases.
Materials and Methods
Network analysis
The network is visualized by Pajek (http://vlado.fmf.uni-lj.si/
pub/networks/pajek/).
miRNA expression profile data
We obtained the normalized gene expression profile of 345
miRNAs in 40 normal tissues that included specimens derived
from brain, muscle, circulatory, respiratory, lymphoid, gastroin-
testinal, urinary, reproductive, and endocrine systems[15]. The
tissue specificity of a miRNA’s expression was calculated based on
the tissue specificity index t proposed by Yanai et al[16]. The t of
miRNA i is defined as
tH~
PnH
j~1 1{
log2SH i,j ðÞ
log2SH i,max ðÞ
hi   
nH{1
where nH is the number of human tissues (here nH=40) and
SH(i,max) is the highest expression value of miRNA i across the nH
tissues.
Figure 3. The distribution of the number of SNP occurring
miRNAs. The blue triangle indicates the distribution of the number of
randomly SNP occurred miRNAs in the miRNAs implicated in at least
one disease. The red arrow indicates the real number of SNP occurred
miRNAs in the miRNAs implicated in at least one disease.
doi:10.1371/journal.pone.0003420.g003
MicroRNAs and Human Disease
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The human miRNAs are classified into conserved miRNAs and
human-specific miRNAs by miRNA family annotations[19]. If a
miRNA has other family members in other species, it will be
treated as conserved miRNAs; otherwise, it will be treated as
human-specific miRNAs. We downloaded human SNP data from
dbSNP by using the University of California, Santa Cruz (UCSC)
genome browser[27].
miRNA sets
In this study, we used two types of miRNA sets: families of
miRNAs and neighboring miRNAs. We first downloaded all the
human miRNAs from miRBase[19]. We next extracted 75 human
miRNA families from miRBase (Supplementary Text S2). As Bartel
et al. reported, 50 kb is an abrupt transition of coexpression
between pairs of miRNAs. MiRNAs separated by ,50 kb showed
high coexpression and miRNAs occurring at a distance of more
than 50 kb showed low coexpression[22]. Using this cutoff, we
identified 65 miRNA clusters (Supplementary Text S3).
Statistical computing
All statistical computations were performed in the statistical
platform ‘‘R’’. Randomization test is performed by randomly
linking the miRNA-disease associations 5000 times and then
calculated the probability of the real case occurs.
Supporting Information
Figure S1 The bipartite graph model. (A) shows a bipartite
graph, which contains two sets of disjoint nodes, here each green
node represents one disease and each blue node represents one
miRNA and the edges between green nodes and blue nodes
represent the associations between miRNAs and diseases. A
miRNA-associated disease network (MDN) is constructed if any
two diseases share one common associated miRNAs, as shown in
(B).
Found at: doi:10.1371/journal.pone.0003420.s001 (6.79 MB TIF)
Figure S2 The human miRNA disease network (MDN). Red
nodes, green nodes and pink nodes represent cardiovascular
diseases, cancers, and other diseases, respectively.
Found at: doi:10.1371/journal.pone.0003420.s002 (2.89 MB TIF)
Text S1 miRNAs with high tissue specificity index values
Found at: doi:10.1371/journal.pone.0003420.s003 (0.00 MB
TXT)
Text S2 miRNA families
Found at: doi:10.1371/journal.pone.0003420.s004 (0.00 MB
TXT)
Text S3 miRNA clusters
Found at: doi:10.1371/journal.pone.0003420.s005 (0.00 MB
TXT)
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